Pilot Study of 18F-FLT PET

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT00585741
First received: December 21, 2007
Last updated: February 22, 2012
Last verified: February 2012

December 21, 2007
February 22, 2012
December 2006
December 2011   (final data collection date for primary outcome measure)
To test whether the cellular response to fractionated radiotherapy leads to observable global change in the uptake of 18F-FLT as assessed by PET imaging [ Time Frame: end of study ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00585741 on ClinicalTrials.gov Archive Site
To assess the technical and logistic feasibility of 18F-FLT scans in a population of cancer patients [ Time Frame: end of study ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Pilot Study of 18F-FLT PET
Pilot Study of 18F-FLT Pet Imaging in Cancer Patients

Fractionated radiotherapy induces an observable change in the proliferative activity as assessed by pre-treatment and early-treatment 18F-FLT PET imaging. This study is designed to investigate 18F-FLT as a PET imaging agent for predicting treatment effectiveness in several tumors and will serve as a pilot study to a planned PO1 submission

Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • CNS Brain Metastasis
  • Head and Neck Cancer
  • Lung Cancer
  • Prostate Cancer
  • Esophageal Cancer
Procedure: Imaging with 18F-FLT PET
Imaging with 18F-FLT PET
  • Experimental: 2. Head and neck
    Imaging with 18F-FLT PET
    Intervention: Procedure: Imaging with 18F-FLT PET
  • Experimental: 3. Lung
    Imaging with 18F-FLT PET
    Intervention: Procedure: Imaging with 18F-FLT PET
  • Experimental: 4. prostate
    Imaging with 18F-FLT PET
    Intervention: Procedure: Imaging with 18F-FLT PET
  • Experimental: 5. esophagus
    Imaging with 18F-FLT PET
    Intervention: Procedure: Imaging with 18F-FLT PET
  • Experimental: 1.CNS
    Imaging with 18F-FLT PET
    Intervention: Procedure: Imaging with 18F-FLT PET
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
15
December 2011
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Able to tolerate a PET/CT scan
  • Age of 18 or older
  • signed informed consent
  • being considered for radiotherapy for treatment of CNS mets, Head and neck cancer, lung cancer, prostate cancer or esophageal cancer

Exclusion Criteria:

  • Prior XRT to site being studied
  • severe claustrophobia or inability to tolerate PET/CT
  • unable to provide written consent
  • pregnant or breastfeeding women
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00585741
HSC-2006-0280
Yes
University of Wisconsin, Madison
University of Wisconsin, Madison
Not Provided
Principal Investigator: Robert Jeraj, Ph.D. University of Wisconsin, Madison
University of Wisconsin, Madison
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP